He encontrado que alguna farmacia puede tener existencias limitadas de ciertos medicamentos, mientras que otras pueden tener casi cualquier formato que se le ocurra y el habitual de dosis habitualidad apareció. En resumen, siempre se contiene el almacén de corroborar. Al mismo tiempo que el producto que más que gustaba ha resultado no estaba disponible en stock otro distinto por las Buenas costumbres también debe buscarse jefe no asн parezca. Por eso es importante disponer de un Plan B para actuar cuandod ello no ocurra.
Ventaja de tomar un genérico en lugar de Asix
Un genérico es más barato que el nombre de marca
Uno de los mayores incentivos para someterse al Dónde comprar Lasix genérico en lugar de pagar la marca es que usted puede obtener un ahorrando importantes Lasix genérico. Por lo tanto, un Lasix genérico es en general mucho más barato que el homólogo de marca, así que una denominación genérica se hace posible para las personas que usan este medicamento con frecuencia. Un ejemplo: La compra de lurosemida en lugar de Lasix es una considerable ahorro para el presupuesto mensual de medicamentos.
Trio_specs_us_1-18-06 revc
Trio_specs_US_1-18-06 RevC 2/1/06 12:35 PM Page 1
T ABLE BEDSIDE MONITORS G e n e r a l D e s c r i p t i o n
The Trio is a portable, configured monitor
designed for use in many hospital departments
and outpatient areas – from traditional bedside
monitoring to intra-hospital transport. Its high-
resolution color display far exceeds the standard
The Trio, with a rechargeable battery, allows you to
continuously monitor vital signs while transporting
S u m m a r y o f F e a t u r e s a n d B e n e f i t s
■ 8.4'' color TFT display with a resolution of
800 x 600 provides optimal visualization of
■ Standard features include up to 4 waveforms,
3 or 5 lead ECG, Respiration, NIBP, SpO2 and
■ Many options available including Masimo SET®
motion tolerant SpO2, Nellcor® OxiMax® SpO2,
invasive blood pressure, Lithium Ion battery and
■ 24 hour graphic and list trends with event
markers provide extended review of all patient
■ Default menu stores user configured settings for
■ Waveform and numeric data are configurable to
■ Ergonomically designed fold-away handle with
■ Built-in Power Supply for direct AC connection
allows for convenient transport from one
■ Navigator™ Control Knob and quick action keys
Trio_specs_US_1-18-06 RevC 2/1/06 12:35 PM Page 2
TrioTM P E R F O R M A N C E S P E C I F I C A T I O N S E C G P u l s e O x i m e t r y
Masimo SET® SpO2 Saturation Accuracy with no motion conditions
Masimo SET® SpO2 Saturation Accuracy during motion conditions
20 seconds to 95% of final step of % SpO2 value from 60–95%
at 75 BPM. Averaging set at 8 seconds.
Nellcor® OxiMax® SpO2 Saturation Accuracy
MAX-A, MAX-AL, MAX-N, MAX-P, MAX-I, MAX-FAST
Pulse Rate Range Masimo with no motion conditions
Pulse Rate Range Masimo during motion conditions
H e a r t R a t e M e t e r E l e c t r i c a l R a t i n g s
Rejects all pulses of amplitude ±2.0 mV to ±700 mV and duration
0.1 ms to 2 ms with no tail per ANSI/AAMI EC13-2002 4.1.4.1
Rejects all pulses of amplitude ±2.0 mV to ±700 mV and duration
0.1 ms to 2 ms with 100 ms time constant tail of less than 2.0 mV, or
4 ms time constant tail of less than 2.0 mV per ANSI/AAMI EC13-2002 4.1.4.2
Tall T-Wave Rejection: Rejects all T-Waves less than 120% of a 1 mV, 100 ms QRS, and a
T-Wave duration of 180 ms and a Q-T interval of 350 ms per ANSI/AAMI
Sealed Lead Acid: 75 minutes from one fully charged new battery at 25 °C with ECG, SpO2, and NIBP every 15 minutes. Lithium Ion: 3 hours from one fully charged new battery at 25 °C with ECG, SpO
E n v i r o n m e n t a l C o n d i t i o n s
-1,000 to 20,000 ft ASL, 1050 hPa to 466 hPa, 788 mmHg to 349 mmHg
I B P I n f o r m a t i o n
-1,000 to 9,889 ft ASL, 1050 hPa to 700 hPa, 788 mmHg to 525 mmHg
ART: 0-150 mmHg, PA: 0-100 mmHg, CVP: 0-40 mmHg, RAP:0-40
Frequency Response: DC to 16 Hz ± 1 Hz, -3 db
4 kg (8.8 lbs) excluding battery & optional accessories
4.66 kg (10.25 lbs) including 1 sealed lead acid battery excluding optional accessories
25 ms, without sensor, measured using a simulator as the input
4.33 kg (9.52 lbs) including 1 lithium ion battery excluding optional accessories
A g e n c y C o m p l i a n c e s N o n - I n v a s i v e B P
This monitor complies with the following industry standards:
IEC 60601-1:1988 +A1:1991, A2:1995/EN 60601-1:1990 +A1:1993, A2:1995,
Measurement Intervals: 1 min, 2 min, 3 min, 4 min, 5 min, 10 min, 15 min, 30 min, 1 hr,
A13:1995, UL 2601-1:1997, CSA Standard C22.2 No.601.1M90, IEC 60601-1-4:1996/
EN 60601-1-4:1996 + A1:1999, IEC 60601-2-30:1999/EN 60601-2-30:2000,
Adult: 40-255 mmHg Pediatric: 40-200 mmHg
IEC 60601-2-34:2000/EN 60601-2-34:2000, IEC 60601-2-27:1994/
Adult: 10-210 mmHg Pediatric: 10-150 mmHg
Mean Error less than ±5 mmHg, Standard Deviation less than ±8 mmHg
Mean Error less than ±5 mmHg, Standard Deviation less than ±8 mmHg
EN 865:1997, EN 1060-1:1995, EN 1060-3:1997, ANSI/AAMI EC13:2002,
ISO 3744:1994, ANSI/AAMI/ISO 10993-1:1997, AAMI SP10:1992, EN 475:1995, EN 1041:1998, EN 980:1996 + A1:1999 + A2:2001, IEC 878:1998, ISO 1000:1992 + A1:1998
T e m p e r a t u r e
IEC 60601-1-2:2001/EN 60601-1-2:2001, IEC 68-2-6:1982 +A1:1983
+A2:1985, IEC 68-2-27:1987, IEC 68-2-37:1973 +A1:1983, IEC 529: 1989,
ISTA: 1998 Procedure 1A, ECRI PB-296892:1979 (Drop and impact)
± 0.1 °C (0–50 °C) exclusive of probe errors± 0.2 °F (32–122 °F) exclusive of probe errors
Datascope Corp., US, Canada & Latin America Patient Monitoring Division R e s p i r a t i o n ( E C G )
800 MacArthur Boulevard Mahwah, NJ 07430-0619Customer Service: 1.800.288.2121 or 201.995.8000
Adult: 6–120 BPM, Pediatric: 6–150 BPM
± 2% or ± 2 breaths per minute, whichever is greater
www.datascope.com
Trio™ and Navigator™ are U.S. trademarks of Datascope Corp. Masimo SET® is a U.S. registered trademark of Masimo
R e c o r d e r
Corp. Nellcor® and OxiMax® are registered trademarks of Nellcor Puritan Bennett Inc. Subject to change.
THE PENSION APPEALS BOARD IN RE THE CANADA PENSION PLAN BETWEEN: ALEIDA H. KONYNENBELT Appellant MINISTER OF HUMAN RESOURCES DEVELOPMENT Respondent Appeal CP07036 The Honourable Mr. Justice F.H. Poulin, Chairman The Honourable John J. Urie for the Board : The Appellant appeals the majority decision of a Review Tribunal dated April 14, 1997, which confir